Seeking Alpha

Clovis Oncology (CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the...

Clovis Oncology (CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the survival of patients with pancreatic cancer vs gemcitabine in a phase III study. Clovis is now ending the development of the drug pending further evaluation of the trial data.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)